BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cellular Biomedicine Group (CBMG) to Manufacture Kymriah® for Novartis in China
Novartis and CBMG China

Cellular Biomedicine Group (CBMG) to Manufacture Kymriah® for Novartis in China

October 4, 2018 By Cade Hildreth (CEO) Leave a Comment

On September 27, 2018, Cellular Biomedicine Group Inc. (NASDAQ: CBMG) announced it entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® in China.

Discover class-defining bioproduction tools.

Kymriah’s Approval History and Geographic Spread

CAR-T is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as living drugs.

Last year, Novartis made history by becoming the first company to bring a CAR-T cell therapy (Kymriah) to market in the United States. Kymriah was approved by U.S. FDA in August 2017 for use in children and adults with ALL. The second CAR-T product, Yescarta by Kite Pharmaceuticals, was approved by FDA in October 2017 for patients with lymphoma.

bitbio

On May 1, 2018, FDA approved Kymriah for a second indication, diffuse large B-cell lymphoma. In August 2018, both Kymriah (and Yescarta) secured approval in Europe, indicating the willingness of European regulators to usher in a new class of cellular immunotherapies.

In September 2018, Health Canada approved Kymriah as the first CAR-T therapy to receive regulatory approval in Canada. Clearly, there is regulatory momentum supporting the global spread of novel CAR-T cell therapies.

Pluristyx

Novartis and Cellular Biomedicine Group (CBMG)

Cellular Biomedicine Group (CBMG) is a leading immuno-oncology company that is conducting immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. Its lab is designed and managed according to both China and U.S. GMP standards.

This latest strategic licensing and collaboration agreement between the Novartis and Cellular Biomedicine Group is significant, because it is extending Novartis’ reach into a massive new healthcare market. With China’s current population of 1.39 billion, the country contains almost one-fifth (18.2%) of the total global population of 7.65 billion.

It also allows Novartis to outsource its manufacturing of Kymriah within China.

iPSC-derived cardiomyocte therapy

As stated by Tony Liu, Chief Executive Officer, CBMG:

“This collaboration with Novartis reflects our shared commitment to bringing the first marketed CAR-T cell therapy Kymriah, a transformative treatment option currently approved in the United States, European Union and Canada for two difficult-to-treat cancers, to China where the number of patients in need remains the highest in the world. Together with Novartis, we hope to bring the first CAR-T cell therapy to patients in China. In addition, we continue to focus on developing CBMG’s pipeline of immuno-oncology assets.”

As stated by Pascal Touchon, Senior VP and Global Head, Cell & Gene, Novartis Oncology:

“Novartis is committed to bringing new hope to children and adults who are suffering from aggressive forms of blood cancer and currently have limited therapeutic options.  We are proud to collaborate with CBMG in China to expand our Kymriah manufacturing capabilities and the potential to facilitate safe and seamless delivery of this innovative, one-time treatment to patients in need.”

Previously, on July 10, 2018, Novartis had signed an agreement to have CELLforCURE manufacture CAR-T products for it in Europe. CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne).

Learn More Novartis and CBMG

To learn more about the strategic licensing and collaboration agreement between the Novartis and CBMG, see the press announcement here.

What impact do you think this partnership will have on the companies involved and global CAR-T market at large? Share your thoughts in the comments.

4.2/5 - (5 votes)

Filed Under: CAR-T, Stem Cell News Tagged With: CAR-T, novartis

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.